flow trial semaglutide kidney outcomes 2024 results in patients with overweight or obesity and chronic disease without diabetes: a randomized double-blind placebo-controlled clinical In the FLOW trial, researchers

Discover the research surrounding Melanotan 1 peptide

If you are considering prescription GLP-1 treatment, you can take the free assessment quiz to see whether a personalized program may be a fit

Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 based therapies: An expert consensus statement using a modified Delphi approach

Should metformin dose be increased first in a patient with type 2 diabetes mellitus, HbA1c 5.8%, taking metformin 500 mg daily, phentermine, and NP thyroid 60 mg daily, with poor diet and exercise compliance, before considering GLP-1 receptor agonists?